Clearmind Medicine (CMND) Reports Additional Positive Safety Topline from CMND-100 Study

Clearmind Medicine (CMND) released additional positive safety topline results from its Phase 2 CMND-100 trial evaluating its lead candidate, CML-101, in treating mild to moderate Alzheimer's disease. As of February 9, 2026, the study showed a 30% reduction in Alzheimer's Disease Assisted Living (ADAL) score, indicating clinically meaningful improvement in functional abilities, with no new safety concerns identified. The trial enrolled 60 participants across 10 centers in the U.S. and Europe. The company plans to discuss the findings with the FDA in the coming weeks and is evaluating the data to guide its next steps in development and potential regulatory filing.